StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc (VRTX) income statement

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$534.20−3.59 (-0.67%)

Close on Nov 17, 2026Market cap $135.40BP/E 31.1Yield –

Vertex Pharmaceuticals Inc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
86.0%
Operating margin
38.0%
Net margin
35.0%
Return on equity, FY2025
22.5%

Financial strength

Current ratio
3.19
Debt to equity
–
Debt to assets
–
Cash to current liabilities
156.0%

Valuation

P/E ratio
31.1
Price to sales
10.76
Price to book
6.69
Dividend yield
–

See a number that looks wrong?